Scientists have discovered that the mystery of long COVID may lie in microscopic blood clots that trap inflammatory molecules and refuse to dissolve, creating a self-perpetuating cycle of illness that could affect 65 million people worldwide.
Story Highlights
- Researchers identify abnormal microclots structurally linked to inflammatory nets in long COVID patients’ blood
- These tiny clots resist normal breakdown and harbor pro-inflammatory molecules that fuel chronic symptoms
- New ultrasound technology shows promise for fragmenting stubborn microclots in laboratory tests
- The discovery provides biological validation for long COVID symptoms previously dismissed as psychological
The Hidden Battle in Your Bloodstream
Deep within the circulatory systems of long COVID patients, a microscopic war rages. Researchers have identified abnormal fibrin clots, barely visible under powerful microscopes, that behave unlike anything seen in healthy blood. These amyloid-like structures resist the body’s natural clot-dissolving mechanisms and become repositories for inflammatory proteins that should have been cleared months ago. The discovery represents a paradigm shift from viewing long COVID as a mysterious post-viral syndrome to understanding it as a tangible, measurable disease process.
The microclots don’t act alone. Scientists have documented their structural association with neutrophil extracellular traps, sticky webs of DNA and proteins that immune cells deploy as a last-ditch defense mechanism. In long COVID patients, these NETs appear to stabilize the microclots, making them even more resistant to breakdown while amplifying the inflammatory response throughout the body.
Watch:
When Blood Becomes a Prison for Inflammation
Proteomic analysis reveals that these microclots function as floating warehouses of destruction, packed with inflammatory cytokines like IL-1β, IL-6, and TNF-α alongside clotting factors that perpetuate their own formation. This creates what researchers describe as a self-perpetuating inflammatory and thrombotic loop. The trapped molecules continue signaling distress throughout the circulatory system, potentially explaining why long COVID symptoms persist for months or years after the initial infection has cleared.
The implications extend beyond simple inflammation. These microclots may create microscopic traffic jams in small blood vessels, reducing oxygen delivery to tissues and contributing to the crushing fatigue, brain fog, and exercise intolerance that define long COVID. Unlike normal blood clots that form during injury and dissolve when healing is complete, these pathological structures appear designed for persistence, resisting the body’s attempts to restore normal circulation.
Sound Waves as Molecular Sledgehammers
The discovery of persistent microclots has sparked innovative treatment approaches. Researchers using lab-on-chip technology have demonstrated that low-intensity focused ultrasound at 150 kHz can fragment these stubborn clots dramatically. In laboratory tests, ultrasound combined with microbubbles and clot-dissolving medication reduced microclot diameter from 19 micrometers to just 7 micrometers while decreasing their overall count tenfold.
Long COVID may be fueled by inflammation and tiny clots – ScienceDaily https://t.co/6uIKILvSzZ
— 💜 Brandy (@longcovid25) January 9, 2026
The ultrasound approach represents a potential paradigm shift from systemic medications that affect the entire body to targeted therapy that could theoretically break up microclots wherever they form. However, this technology remains in preclinical development, with no human trials yet conducted. The concept raises intriguing possibilities for non-invasive treatment that could address the root cause rather than just managing symptoms.
Beyond Skepticism Toward Solutions
The microclot hypothesis provides biological validation for patients whose symptoms have been questioned or dismissed. Artificial intelligence models using NET and microclot biomarkers can distinguish long COVID patients from healthy individuals with remarkable accuracy, offering hope for objective diagnostic tests. This mechanistic understanding shifts the conversation from whether long COVID is real to how quickly science can translate discoveries into treatments.
Current therapeutic approaches remain limited to rehabilitation and symptom management, though researchers are exploring antivirals, metformin, immune modulators, and microbiome interventions. The challenge lies in conducting large-scale trials when millions of patients need answers now. The microclot discovery provides a concrete target for drug development, potentially accelerating the timeline from laboratory bench to patient bedside for this devastating condition.
Your instant doctor companion – online 24 hours a day.
Sources:
EurekAlert – Scientists identify abnormal blood clotting mechanism in long COVID patients
Medical Design & Outsourcing – Low-intensity ultrasound for long COVID microclots
Anadolu Agency – Scientists identify abnormal blood clotting mechanism in long COVID patients
Frontiers in Bioengineering and Biotechnology – Microclot fragmentation study
ScienceDaily – Long COVID may be fueled by inflammation and tiny clots
PMC – Microclots and NETs in long COVID research
Harvard Medical School – The most important question about long COVID
1Day Sooner – Long-term risks FAQ
Gavi – Bad blood? The uncertainty around microclots and Long COVID
